Pluristem Therapeutics, Inc. (PSTI)
-NasdaqCM 3.05 0.00(0.00%) 18 May 03:59 SGT
| Prev Close: | 3.05 |
|---|
| Open: | 3.02 |
|---|
| Bid: | 2.49 x 100 |
|---|
| Ask: | 3.18 x 100 |
|---|
| 1y Target Est: | 5.04 |
|---|
| Beta: | 1.35 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 3.00 - 3.06 |
|---|
| 52wk Range: | 2.26 - 5.00 |
|---|
| Volume: | 116,712 |
|---|
| Avg Vol (3m): | 185,621 |
|---|
| Market Cap: | 178.85M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.35 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- PLURISTEM THERAPEUTICS INC FinancialsEDGAR Online Financials(Wed, 15 May)
- 3 Healthcare Stock Stories For Monday Investment Wellnessat Wall St. Cheat Sheet(Tue, 14 May)
- Pluristem Therapeutics' PLX cells may be effective in treating preeclampsiaat theflyonthewall.com(Mon, 13 May)
- Preclinical Research Shows PLX Cells May be Effective in Treating PreeclampsiaGlobeNewswire(Mon, 13 May)
- PLURISTEM THERAPEUTICS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, 8 May)
- Pluristem Therapeutics announces Phase 1 trial to study PLX-PAD cellsat theflyonthewall.com(Wed, 8 May)
- Pluristem Carving Out Distinct Niche in Orthopedic Medicine With New Clinical Trials in Rotator Cuff RepairMarketwired(Wed, 8 May)
- Pluristem Develops PLX-RAD Cells for Use in HematologyGlobeNewswire(Tue, 7 May)
- U.S. judge gives onetime 'King of Biotech' four years in prisonat Reuters(Fri, 3 May)
- United Therapeutics' Second PAH Stumble Emphasizes The Need For Pluristem's Therapyat Seeking Alpha(Tue, 30 Apr)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 261.09 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jun-13)
: | -0.37 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.09 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Pluristem Therapeutics Inc., a bio-therapeutics company, engages in the research, development, and commercialization of standardized cell therapy products and related technologies for the treatment of life threatening diseases.
View More 
0.09%